Actinium Pharmaceuticals, Inc. ATNM 深 沪
已收盘 02-06 16:00:00 美东时间
1.15
-0.010
-0.86%
华盛通- 最 高1.19
- 今 开1.19
- 成交量 9.40万股
- 最 低 1.15
- 昨 收 1.16
- 总市值 3587.53万
- 52周最高 2.41
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 1.0292
- 委 比 -33.33%
- 总股本 3119.59万
- 历史最高 450.00
- 量 比 0.82
- 振 幅 3.45%
- 历史最低 1.0292
- 每 手 1
- 风险率 0.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Actinium Pharma Advances Solid-Tumor Program With Phase 1 Clinical Trial In South Africa Targeting B7-H3
Actinium Pharmaceuticals (NYSE:ATNM), a company developing targeted alpha radiotherapies, is advancing its solid-tumor program with a Phase 1 clinical trial in South Africa targeting B7-H3. This study represents one of
2025-12-09 03:48
Actinium Pharma To Present Preclinical Data For ATNM-400, Actinium-225 Antibody Radioconjugate, In HR+, HER2+ And Triple-Negative Breast Cancer At SABCS 2025
Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment options ATNM-400 overcomes HER2 therapy resistance and represents a novel
2025-12-01 21:49
Actinium To Present New Breast Cancer Data On Its ATNM-400 Radiotherapy At San Antonio Symposium
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that new preclinical data for its lead antibody
2025-11-04 20:34
Actinium Pharmaceuticals Presents New Preclinical Data For ATNM-400 Antibody Radioconjugate At 32nd Annual Prostate Cancer Foundation Scientific Retreat In Carlsbad, California
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today highlighted new preclinical data for ATNM-400, its novel,
2025-10-24 20:31
Actinium Pharmaceuticals Announces That The First-Ever Preclinical Data From Its ATNM-400 Program In Non-Small Cell Lung Cancer Has Been Accepted For Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics Being Held October 22 – 26, 2025
NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever preclinical data from
2025-10-14 00:14
Actinium Pharma Reports Additional Preclinical Data Supporting ATNM-400 Radiotherapy Prostate Cancer Candidate At Annual TRP Summit
- ATNM-400 demonstrates robust efficacy in prostate cancer tumor models with acquired resistance to Pluvicto® and enzalutamide, follow-up continues- ATNM-400
2025-07-31 20:33
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
2025-06-25 08:39
Actinium Pharma Reports New Preclinical Data From Non-PSMA Targeting Radiotherapy Prostate Cancer Candidate ATNM-400, At SNMMI Annual Meeting
- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination- ATNM-400 is
2025-06-23 23:33
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
2025-05-14 08:48
美股大行评级 | 潜在涨幅455.56%！Medicus Pharma获D. Boral Capital升目标价至27美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1128971739548127232.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• D. Boral Capital：维持Medicus Pharma(MDCX)"买入"评级，目标价从14美元升至27美元</p> <p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从
2025-05-13 08:50
